Dyne Therapeutics (DYN) Non-Current Assets (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Non-Current Assets of $56.1 million for Q2 2026, up 80.8% year-over-year from $31.0 million in Q2 2025, and down 4.75% quarter-over-quarter from $58.9 million in Q1 2026.
Dyne Therapeutics (DYN) Non-Current Assets (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Non-Current Assets for 8 consecutive years, with $56.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets rose 80.8% year-over-year to $56.1 million; the TTM figure through Jun 2026 stood at $206.9 million (up 62.87% YoY), while the FY2025 annual figure was $31.2 million, down 2.36% from the prior year.
- Non-Current Assets fell to $56.1 million in Q2 2026 per DYN's latest filing, from $58.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $60.8 million in Q3 2025 and bottomed at $31.0 million in Q2 2025.
- Historically, Non-Current Assets has averaged $40.0 million across 5 years, with a median of $37.6 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 833.05% — and 2024, when it retreated 13.42%.
- Dyne Therapeutics' Non-Current Assets stood at $40.7 million in 2022, then slipped by 12.33% to $35.7 million in 2023, then slipped by 10.51% to $32.0 million in 2024, then retreated by 2.36% to $31.2 million in 2025, then soared by 79.88% to $56.1 million in 2026.
- Business Quant data shows DYN's Non-Current Assets at $56.1 million in Q2 2026, $58.9 million in Q1 2026, and $31.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 56.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.12 Mn |
| Mar 31, 2026 | 58.92 Mn |
| Dec 31, 2025 | 31.20 Mn |
| Sep 30, 2025 | 60.80 Mn |
| Jun 30, 2025 | 31.04 Mn |
| Mar 31, 2025 | 31.57 Mn |
| Dec 31, 2024 | 31.96 Mn |
| Sep 30, 2024 | 32.45 Mn |
| Jun 30, 2024 | 33.56 Mn |
| Mar 31, 2024 | 34.14 Mn |
| Dec 31, 2023 | 35.71 Mn |
| Sep 30, 2023 | 37.03 Mn |
| Jun 30, 2023 | 38.25 Mn |
| Mar 31, 2023 | 39.43 Mn |
| Dec 31, 2022 | 40.73 Mn |
| Sep 30, 2022 | 41.45 Mn |
| Jun 30, 2022 | 42.09 Mn |
| Mar 31, 2022 | 43.31 Mn |
| Dec 31, 2021 | 43.27 Mn |
| Sep 30, 2021 | 42.22 Mn |